IFNB1 and myeloid sarcoma: This fact showed us that IFNβ therapy was able to decrease significantly LINE-1 methylation levels in MS patients without clinical activity but hypermethylation was maintained at the same levels as before the onset of therapy in patients in whom the treatment was not effective in decreasing clinical activity.One explanation could be that, as Searles Nielsen et al. reported, the persons with less ability to respond to a changing environment may be at increased risk of developing a variety of neurological disorders45.